Doxycycline postexposure prophylaxis has the potential to substantially reduce real-world population-level incidence of ...

DoxyPEP is reducing the rate of syphilis and chlamydia but has had little to no effect on gonorrhea and needs close monitoring for antibiotic resistance.

Both studies in JAMA Internal Medicine supported the rising profile of doxyPEP as a way to counter the epidemic of syphilis, gonorrhea, and chlamydia infections, even if the data ...

As health care services begin offering doxycycline to prevent bacterial sexually transmitted infections (STIs), real-world evidence demonstrates that the postexposure strategy, called doxy PEP, is ...